**Core tip:** Human class B scavenger receptor I (SR-BI) plays important roles in both host lipid metabolism and the entry of hepatitis C virus (HCV). Single nucleotide polymorphisms (SNPs) in the host genome that affect the virus-host interaction have received increasing attention in recent years. Several SR-BI SNPs have been reported to affect the high-density lipoprotein cholesterol levels in populations carrying SR-BI mutations; however, the impact of SR-BI SNPs on HCV infection has not been studied intensively. Based on our results, the S112F single amino acid mutation in SR-BI inhibited the infectivity of hepatitis C virus derived from cell culture in a cell culture model by downregulating the expression of the SR-BI protein.

INTRODUCTION
============

Hepatitis C virus (HCV) is an enveloped RNA virus that belongs to the *Hepacivirus* genus of the *Flaviviridae* family. The HCV genome encodes a large precursor polyprotein, which is cleaved by host and viral proteases to generate at least 10 functional viral proteins\[[@B1]\]. HCV infection is a global health problem, with an estimated 180 million persons infected worldwide, and HCV infection is the leading cause of cirrhosis and hepatocellular carcinoma\[[@B2]\]. The prevalence of chronic HCV infection in China was 3.2% in 1992 and 0.4% in 2006. Recent reports from the Chinese Ministry of Health have identified 70861 cases in 2006 and 201622 cases in 2012\[[@B3]\]. The most recent investigation showed a prevalence of HCV infection of 3.0% in northeastern China\[[@B4]\]. In recent years, the Chinese government has increased its investment in the prevention and control of viral hepatitis. However, an effective vaccine is not available and treatment with the combination of interferon and ribavirin therapy produces a response in approximately half of infected patients. More recently, a new therapy comprising novel direct-acting antivirals (DAAs), such as protease inhibitors (telaprevir, boceprevir and simeprevir) and an RNA polymerase inhibitor (sofosbuvir), increased the sustained virological response rate in HCV-infected patients\[[@B5]-[@B7]\]. However, the DAA therapy also produces significant side effects\[[@B8]\]. Therefore, novel anti-HCV methods, including host targets, are still needed.

HCV entry is a multi-step process that requires many host molecules, including the tetraspanin molecule CD81, human class B scavenger receptor I (SR-BI), and the tight-junction proteins claudin-1 (CLDN1) and occludin (OCLN)\[[@B9]-[@B12]\]. Among these proteins, SR-BI plays a crucial role since both SR-BI and its ligand lipoprotein are involved in the HCV entry process\[[@B13],[@B14]\]. SR-BI has a number of common ligands, including high-density lipoprotein (HDL), low-density lipoprotein (LDL) and oxidized LDL\[[@B13]\]. As shown in a study by Dreux et al\[[@B15]\], HDL enhances the infectivity of HCVpp (HCV pseudoparticles) and hepatitis C virus derived from cell culture (HCVcc).

SR-BI was originally defined as a class B scavenger receptor in a family that includes CD36, LIMP II (lysosome membrane protein II), and SR-BII (a form of SR-BI with an alternate C-terminal cytoplasmic tail)\[[@B16]\]. SR-BI is a lipoprotein receptor composed of 509 amino acids (aa) in which the cytoplasmic C- and N-terminal domains are separated by a large extracellular domain. As an HDL receptor, SR-BI mediates selective uptake of HDL-derived cholesteryl ester (CE) *in vitro* and *in vivo*\[[@B17]\]. The conformation of the extracellular domain is important for the binding of SR-BI and HDL, and hence affects the function of SR-BI\[[@B18]\]. Eleven N-linked glycosylation sites (aa102, 108, 116, 173, 212, 227, 255, 288, 310, 330 and 383) have been identified in the extracellular domain, and two glycosylation sites (Asn108 and Asn173) were proven to be indispensable for the expression and function of SR-BI\[[@B19]\]. In addition to mediating selective CE transport, SR-BI has been shown to play important roles in many human diseases, including atherosclerosis, apoptosis, immune responses, HCV and dengue virus entry, and malaria parasite infection\[[@B20]\].

In recent years, the influence of single nucleotide polymorphisms (SNPs) in the host genome on the virus-host interaction has received increasing attention. For HCV, most studies have focused on SNPs in the *IL28B* gene and HCV prognosis\[[@B21]\]. Currently, few reports on virus entry and host genomic SNPs have been published\[[@B22]\]. For SR-BI, researchers have focused on its regulation of HDL-cholesterol and other metabolites, and a very recent report showed that polymorphisms in the SR-BI gene are associated with the virological response in HCV-infected patients\[[@B23],[@B24]\]. According to the results of a GWAS (genome-wide association study) of 10000 individuals, SNPs in the SR-BI gene are associated with a small, but significant elevation in plasma HDL-cholesterol levels\[[@B25]\]. Recently, a single loss-of-function mutation (P297S) in SR-BI was identified, and the mutation increased HDL-cholesterol levels and reduced cholesterol efflux from macrophages\[[@B26]\]. Subsequently, two novel missense mutations, S112F (nucleotide C588T) and T175A (nucleotide A776T) were also shown to be associated with elevated HDL-cholesterol levels\[[@B27],[@B28]\]. However, few studies have investigated how the mutations impact HCV infection and development. In this study, we studied the effects of the SR-BI S112F single amino acid mutation on the infectivity of HCVcc using a cell culture model.

MATERIALS AND METHODS
=====================

Materials
---------

The Huh7 cell line, human embryonic kidney (HEK) 293T cell line and Huh7-siSR-BI cell line are maintained in our laboratory. Briefly, SR-BI shRNA was designed, cloned into the pGP-Lenti3 vector (Biovector, Science Lab, Beijing), and the positive recombinant Lv-SR-BI-shRNA vector was verified. This vector and helper plasmids were co-transfected into HEK 293T cells. The recombinant lenti-SR-BI-shRNA virus was used to infect Huh7 cells. Puromycin was added for screening, and real-time PCR and Western blot were conducted to detect the levels of the SR-BI mRNA and protein, respectively; finally, the Huh7-siSR-BI cell line was obtained\[[@B29]\].

Cells were grown in complete Dulbecco's Modiﬁed Eagle's Medium (DMEM; Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco BRL, United States), 1 mmol/L -glutamine, 100 nmol/L nonessential amino acids, 100 U/mL penicillin, and 100 μg/mL streptomycin.

Construction of SR-BI S112F plasmid expressing the SR-BI single amino acid mutation
-----------------------------------------------------------------------------------

The SR-BI S112F mutation was introduced into pcDNA-SR-BI (maintained in our lab) using a Quick Change Lightning Site-Directed Mutagenesis Kit (Stratagene, CA, United States), according to the manufacturer's instructions, with the primers (S112F-F: 5'-ACAACGACACCGTG*T*TCTTCCTCGAGTACCGCACCT-3' and S112F-R: 5'-AGGTGCGGTACTCGAGG*A*AGAACACGGTGTCGTTGT-3'; the italic letters represent the mutant nucleotide). The presence of the desired mutation was confirmed using nucleotide sequencing (Invitrogen, CA, United States).

Quantitative real-time RT-PCR (qRT-PCR)
---------------------------------------

RNA was isolated from harvested cells using TRIzol reagent (Invitrogen), and RNA was prepared according to the manufacturer's instructions. RNA obtained from 1 × 10^5^ cell equivalents was analyzed using RT-PCR. RNA samples were transcribed into cDNA using random primers and then quantitatively analyzed with the specific primers SR-BI-F: 5'-GCTGCAGGAA GCAAAACTGT-3' and SR-BI-R: 5'-CCAGTAGAAAAGGG TCACAGG-3' using the quantitative RT-PCR kit (Applied Biosystems, United States). Genome copy numbers were normalized to GAPDH levels determined in parallel (GAPDH-F: 5'-TGACTTCAACAGCGACACCCA-3'; GAPDH-R: 5'-CACCCTGTTGCTGTAGCCAAA-3') using the comparative cycle threshold values.

Immunofluorescence assays
-------------------------

Huh7 and SR-BI knock-down Huh7-siSR-BI cells were cultured in collagen-coated 96-well plates at a density of 1 × 10^4^ cells/well on the day before transfection. Cells were transfected with the SR-BI wild type (WT) and SR-BI S112F plasmids using Lipofectamine^TM^ (Invitrogen, CA, United States), according to the manufacturer's instructions. Fresh cell medium was replaced 6 h after transfection and the cells were cultured for 48 h. Cells were washed with PBS, fixed with cold methanol, and then stained with an anti-SR-BI mouse monoclonal antibody (mAb) (1:1000 dilution, BD, United States) or serum from HCV-infected patients (1:100 dilution) for 2 h at room temperature (RT). After being washed with PBS, cells were reacted with an Alexa Fluor 488-conjugated anti-mouse antibody or human IgG antibodies (1:1000 dilution, BD, United States). Nuclei were stained with DAPI (1:2000 dilution, BD, United States). Images were captured and infected foci were counted under a fluorescence microscope (Olympus IX81, Japan).

Western blot analysis
---------------------

Protein extracts from transfected cells were prepared in a modified RIPA buffer containing 0.5% SDS and a protease inhibitor cocktail (Complete mini; Roche) on ice. After centrifugation, protein concentrations were determined using the BCA method (Beyotime). The proteins were separated using 10% (w/v) SDS-polyacrylamide gel electrophoresis and transferred onto PVDF membranes (Millipore, Billerica, MA, United States) using a Trans-Blot apparatus (Bio-Rad). Membranes were blocked with 5% nonfat milk, incubated with a primary anti-SR-BI mouse mAb (1: 2000 dilution, BD), and detected using a horseradish peroxidase (HRP)-conjugated species-specific secondary antibody (Santa Cruz Biotechnology). Immunoreactivity was visualized using enhanced chemiluminescence (GE Healthcare).

HCVcc production and HCV infection assay
----------------------------------------

The pJFH1 plasmid, which was kindly provided by Dr. Takaji Wakita (National Institute of Infectious Diseases, Tokyo, Japan), was used as template to generate HCVcc as described\[[@B30]\]. Briefly, pJFH-1 was linearized to generate the template used in the *in vitro* transcription reaction to produce the viral RNA using the MEGAscript kit (Promega, Madison, WI, United States). Huh7 cells were then transfected with JFH-1 transcripts by electroporation. Cell culture supernatants were collected 5 d later and the viral titer was quantified. For the infection assay, Huh7-siSR-BI cells were seeded in a 96-well plate, cultured in 10% FBS-DMEM overnight, and then infected with HCVcc. The cells were cultured for 48 h before the infectivity was measured using the immunofluorescence assays.

HCVpp production and HCV entry assay
------------------------------------

HCVpp were generated as described\[[@B31]\]. Briefly, HEK 293T cells were transfected with plasmids encoding the HCV envelope proteins, Gag/Pol (pLP1) and Rev (pLP2) and the pLenti6 transfer vector (Invitrogen) expressing the luciferase gene. Vesicular stomatitis virus pseudoparticles were produced as controls. Cell culture supernatants were collected 2 d later and the viral titer was quantified using immunofluorescence assay (IFA). For the HCV entry assay, Huh7-siSR-BI cells were seeded on a 96-well plate, cultured overnight, and transfected with pCDNA-SR-BI WT and mutant plasmids, inoculated with HCVpp, and then cultured for 72 h before the entry of HCVpp was measured using a fluorescence assay.

SR-BI and HCV E2 protein binding assay
--------------------------------------

The SR-BI and HCV E2 protein binding assay was performed using a FACS-based assay, as previously described\[[@B32]\]. Briefly, 4 × 10^5^ CHO cells expressing SR-BI were incubated with equivalent amounts of HCV E2 protein (transient expression in HEK 293T cells) for 1 h at RT, washed twice with PBS, and incubated with an anti-E2 mAb (1 h at RT). After labeling with Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen), the mean fluorescence intensity was quantified by flow cytometry (Beckman Coulter, Fullerton, CA, United States).

DiI-HDL uptake assay of SR-BI WT and mutant
-------------------------------------------

Huh7-siSR-BI cells were seeded in a 96-well plate at a density of 2 × 10^4^ cells/well and cultured for 24 h. Cells were transfected with the SR-BI WT and mutant S112F plasmids using Lipofectamine^TM^. Complete culture medium was replaced 6 h after transfection and the cells cultured for 48 h before DiI-HDL (200 μg/mL, Alfa Aesar, United States) was added and the cells were cultured for an additional 4 h. Nuclei were stained with Hoechst (Merk, NJ, United States) for 10 min, and cells were observed and images captured using a microscope.

Statistical analysis
--------------------

The error bars represent the SD of means from at least three independent experiments. Statistical significance was analyzed using Student's *t* test. *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Generation of the SR-BI S112F mutant
------------------------------------

The pcDNA-SR-BI/S112F vector expressing the SR-BI single amino acid mutant was obtained by site-directed mutagenesis and confirmed by nucleotide sequencing. The Ser at site 112 was replaced with Phe in the mutant.

SR-BI S112F mutation decreases HCV entry
----------------------------------------

Huh7-siSR-BI cells were transfected with pcDNA3.1, pcDNA-SR-BI, or pcDNA-SR-BI/S112F first, and infected with HCVpp expressing the luciferase gene 3 d after transfection. Fluorescence was detected 3 d later. Compared with cells transfected with the pcDNA3.1 vector control and pcDNA-SR-BI WT control, SR-BI S112F decreased the entry of HCV in Huh7-siSR-BI cells (Figure [1](#F1){ref-type="fig"}).

![Effect of the class B scavenger receptor I single amino acid mutant on hepatitis C virus entry. Huh7-siSR-BI cells were seeded on a 96-well plate, cultured overnight, and transfected with pcDNA3.1 (NC), pcDNA-SR-BI, or pcDNA-SR-BI/S112F. Three days after transfection, HCVpp were added to the cell culture. Cells were harvested 72 h post infection and cell lysates were analyzed using a fluorescence assay. The data are presented as the mean ± SEM from three independent experiments (^a^*P* \< 0.05). WT: Wild type.](WJG-23-5158-g001){#F1}

SR-BI S112F mutation decreases HCVcc infection
----------------------------------------------

Huh7-siSR-BI cells were seeded in 96-well plates (for IFA) or 24-well plates (for qRT-PCR) and transfected with pcDNA3.1, pcDNA-SR-BI, or pcDNA-SR-BI/S112F; HCVcc (10^3^FFU/mL) was added 24 h after transfection. Cells were harvested 72 h after infection and RNA was isolated for qRT-PCR. IFA was performed 48 h later. According to the IFA results, the expression of the HCV protein was decreased in the pcDNA-SR-BI/S112F group (Figure [2A](#F2){ref-type="fig"}). Based on the qRT-PCR results, the level of the HCV RNA was decreased in the pcDNA-SR-BI/S112F group (0.711 of the WT level), compared with pcDNA3.1 vector control and pcDNA-SR-BI WT control (Figure [2B](#F2){ref-type="fig"}).

![Effect of the class B scavenger receptor I single amino acid mutant on hepatitis C virus infectivity. A: Immunofluorescence assay (IFA) of the effects of the SR-BI single amino acid mutant on hepatitis C virus (HCV) infectivity. Huh7-siSR-BI cells were seeded in 96-well plates, cultured overnight, and then transfected with pcDNA3.1 (NC), pcDNA-SR-BI (WT), or pcDNA- SR-BI/S112F. HCVcc (10^3^ FFU/mL) was added 24 h after transfection, and the IFA was performed 48 h later. B: Effect of the SR-BI single amino acid mutant on the HCV viral RNA. Huh7-siSR-BI cells were seeded in 24-well plates, cultured overnight, and then transfected with pcDNA3.1 (NC), pcDNA-SR-BI, or pcDNA-SR-BI/S112F. HCVcc (10^4^ FFU/mL) was added 24 h after transfection, and cells were harvested 72 h later to prepare RNA for the qRT-PCR analysis (^a^*P* \< 0.05). SR-BI: Class B scavenger receptor I; WT: Wild type.](WJG-23-5158-g002){#F2}

S112F mutation decreases the expression of the SR-BI mRNA and protein
---------------------------------------------------------------------

Huh7-siSR-BI cells were transfected with pcDNA3.1, pcDNA-SR-BI and pcDNA-SR-BI/S112F. Forty-eight hours after transfection, cells were harvested and analyzed by Western blot and qRT-PCR, and the results showed that the levels of the SR-BI S112F mRNA and protein were decreased compared with SR-BI WT cells (Figure [3](#F3){ref-type="fig"}).

![Effects of the single amino acid mutant on class B scavenger receptor I mRNA and protein expression. A: Effect of the single amino acid mutant on SR-BI protein expression. Huh7-siSR-BI cells were seeded in 24-well plates, cultured overnight, and transfected with pcDNA3.1 (NC), pcDNA-SR-BI, or pcDNA-SR-BI/S112F. Cells were harvested 72 h after transfection and lysed with RIPA cell lysis buffer; Western blot was performed to analyze the expression of the SR-BI protein. B: Effect of the single amino acid mutant on the SR-BI mRNA level. Huh7-siSR-BI cells were seeded in 24-well plates, cultured overnight, and then transfected with pcDNA3.1 (NC), pcDNA-SR-BI (WT), or pcDNA-SR-BI/S112F (S112F). Cells were harvested 72 h after transfection and RNA was isolated and the level of the SR-BI mRNA was analyzed using qRT-PCR (^a^*P* \< 0.05; ^b^*P* \< 0.001). SR-BI: Class B scavenger receptor I; WT: Wild type.](WJG-23-5158-g003){#F3}

SR-BI S112F mutation impairs the binding of SR-BI to the HCV E2 protein
-----------------------------------------------------------------------

SR-BI has been reported to bind to HCV E2 protein. The ability of CHO cells expressing WT and mutant SR-BI to bind to the HCV E2 protein that had been expressed in HEK 293T cells was analyzed, and the results showed that the S112F mutation impaired the binding of SR-BI to the HCV E2 protein (Figure [4](#F4){ref-type="fig"}). We also performed the binding assay using HCVcc instead of the expressed HCV E2 protein and obtained similar results.

![Ability of the class B scavenger receptor I single amino acid mutant to bind to the hepatitis C virus E2 protein. CHO cells expressing the wild type (WT) and mutant SR-BI protein were incubated with equivalent amounts of hepatitis C virus E2 protein that had been expressed in HEK 293T cells for 1 h at RT, washed twice, and incubated with an anti-E2 mAb for 1 h at RT. After labeling with Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen), the mean fluorescence intensity was quantified by flow cytometry (^a^*P* \< 0.05). SR-BI: Class B scavenger receptor I.](WJG-23-5158-g004){#F4}

SR-BI S112F mutation decreases HDL uptake by SR-BI
--------------------------------------------------

We performed the HDL uptake assay with DiI-HDL to determine whether the single amino acid mutation affects the HDL uptake ability of SR-BI. Huh7-siSR-BI cells were first transfected with SR-BI WT and mutant S112F plasmids, and then DiI-HDL was added. Based on the microscopic images, the S112F mutation decreased HDL uptake compared with SR-BI WT (Figure [5](#F5){ref-type="fig"}).

![Effect of the single amino acid mutant on high-density lipoprotein absorption by class B scavenger receptor I. Huh7-siSR-BI cells were seeded in a 96-well plate and cultured overnight prior to transfection. Cells were transfected with the SR-BI wild type (WT) and mutant S112F plasmids using LipofectamineTM. Complete culture medium was replaced 6 h after transfection and cells were cultured for 48 h before DiI-HDL (200 μg/mL) was added, and the cells were cultured for an additional 4 h. Nuclei were stained with Hoechst for 10 min, and cells were observed and images captured using a microscope (^b^*P* \< 0.01). SR-BI: Class B scavenger receptor I.](WJG-23-5158-g005){#F5}

DISCUSSION
==========

The SR-BI receptor is associated with lipid metabolism and participates in the bidirectional transport of cholesterol between cells and HDL. Increased clearance of HDL-CE from plasma and enhanced reverse cholesterol transport have been shown to significantly reduce atherosclerosis in animal models\[[@B23]\]. Previous studies have confirmed that the extracellular domain of SR-BI is critical for its receptor function\[[@B19]\].

Recently, the functions of SNPs in the SR-BI gene have been studied both in human and animal models. Acton and colleagues were the ﬁrst to identify the associations between SNPs in the SR-BI gene and plasma lipid levels and body mass index in a Caucasian European population\[[@B33]\]. The nonsynonymous exon 1 SNP (rs4238001 \[G2S\]), which encodes a different amino acid, was signiﬁcantly associated with higher HDL cholesterol (HDL-C) and lower LDL cholesterol (LDL-C) levels\[[@B33]\]. In 2011, a P297S missense mutation in SR-BI was reported, and people who carry the P297S mutation have increased HDL cholesterol levels\[[@B26]\]. Then, two novel missense mutations, S112F and T175A, in human SR-BI were identified in patients with atherosclerosis, which led to elevated HDL cholesterol levels\[[@B27]\]. A coding variant in SR-BI (I179N) significantly increased atherosclerosis, although the mutation did not dramatically affect the plasma lipid levels\[[@B34]\]. The hydrophobicity of N-terminal half of the extracellular domain of SR-BI was proven to be critical for the SR-BI-mediated cholesterol transport function, and this domain might function by interacting with other integral membrane proteins\[[@B35]-[@B37]\]. S112F, T175A and I179N point mutations occurred in the same region, but had different effects on the function of SR-BI and require further study.

HCV infection is a complicated process and is closely correlated with host lipid metabolism. In the attachment step, the HCV lipoviral particle (LVP) is recruited and binds to glycosaminoglycans on heparan sulfate and low-density lipoprotein receptor on host cells; then, HCV enters hepatocytes by interacting with several host entry factors, including CD81, SR-BI, the tight junction proteins CLDN1 and OCLN, and the cholesterol absorption receptor Niemann-Pick C1-like-1\[[@B38]\]. Lipids and lipid receptors play key roles in the early stage of HCV infection, and researchers have postulated that LVP was actually endocytosed into the hepatocytes as a regular lipoprotein\[[@B39]\].

During the entry step, the HCV E2 HVR1 region interacts with the extracellular loop of SR-BI in both the binding and post-binding steps\[[@B40],[@B41]\]. Therefore, strategies targeting SR-BI have been reported to inhibit HCV infection. SR-BI binds to serum amyloid A (SAA), an acute-phase protein produced by the liver, promoting SAA internalization and inhibiting HCV entry\[[@B42]\]. A small-molecule antiviral compound, ITX5061, has been reported to impede the uptake of HDL by SR-BI and blocks the uptake of HCV viral particles by hepatocytes\[[@B43],[@B44]\].

In addition to the entry step, the replication of HCV in the membrane web and release from hepatocytes are associated with the host lipid metabolism. Since SR-BI has a key role in the host lipid metabolism and SNPs in the SR-BI gene have been reported to modulate the function of SR-BI, we studied the effect of the S112F missense mutation in SR-BI on the infectivity of HCVcc in SR-BI knock-down Huh7 cells. The Huh7-siSR-BI cell line was established by screening Huh7 cells with puromycin after infection with Lv-SR-BI-shRNA\[[@B29]\]. We first constructed SR-BI S112F using site-directed mutagenesis, and then Huh7-siSR-BI cells were used to detect the effects of the single amino acid mutant in SR-BI on the entry and infectivity of HCV. The S112F single amino acid mutation decreased HCV entry and the infection of HCVcc compared with SR-BI WT. We further assessed the effects of S112F on the SR-BI mRNA and protein levels to determine how the S112F mutation affected SR-BI, and the results showed that the levels of both the SR-BI mRNA and protein decreased when Ser112 was replaced with Phe. Then, we detected the ability of SR-BI S112F to bind to HCV E2 and showed that the binding ability decreased, potentially due to the decreased level of the SR-BI protein. Finally, since the S112F mutation is associated with an abnormal HDL level and HCV replication is closely correlated with lipid metabolism, we measured the HDL uptake ability of SR-BI S112F and observed a decrease compared with SR-BI WT.

We performed a literature search to determine why the S112F mutant significantly decreased the expression of SR-BI and found that Ser112 is located in the extracellular domain of SR-BI. SR-BI and LIMP II belong to the same family and share 34% sequence identity and 56% sequence homology. The X-ray crystal structure of the extracellular domain of human LIMP II has been solved. Therefore, we used the LIMP II structure as a guide to generate a homology model of human SR-BI. Ser112 in SR-BI is located in a hydrophilic pocket, which is conserved in SR-BI. If the serine (hydrophilic amino acid) is mutated to phenylalanine (hydrophobic amino acid), this hydrophilic pocket will be destroyed. Thus, the protein will not fold correctly, which might be responsible for the downregulation of SR-BI expression in cells expressing the SR-BI S112F mutant.

In summary, we constructed the S112F single amino acid SR-BI mutant and analyzed the effects of this mutant on HCV entry and infectivity. The S112F single amino acid mutant decreased the levels of the SR-BI mRNA and protein and subsequently reduced the binding of SR-BI to HCV E2 protein, as well as the SR-BI-dependent HCV entry and infectivity of HCVcc. In this study, Huh-7-siSR-BI cells expressing SR-BI S112F also showed decreased HDL uptake, but the effects of this mutation on the release of progeny viruses require further investigation.

COMMENTS
========

Background
----------

Human class B scavenger receptor I (SR-BI) is an important receptor associated with host lipid metabolism, and both SR-BI itself and its ligands also play crucial roles in the life cycle of hepatitis C virus (HCV). Single nucleotide polymorphisms (SNPs) in the host genome that affect the virus-host interaction have received increasing attention in recent years. SNPs in the *IL28B* gene are associated with HCV prognosis.

Research frontiers
------------------

SNPs in the SR-BI gene are reported to be associated with the elevated plasma HDL-cholesterol levels and virological response of HCV-infected patients. However, the relation between SR-BI SNPs and HCV infectivity has not yet been clearly identified.

Innovations and breakthroughs
-----------------------------

This study is the first to evaluate the effect of the single amino acid polymorphism SR-BI S112F on the infectivity of hepatitis C virus derived from cell culture (HCVcc) using a cell culture model. SR-BI S112F inhibited HCVcc infectivity by downregulating the expression of the SR-BI protein.

Applications
------------

Based on the results from the present study, the SR-BI S112F single amino acid mutant affected both HCV entry and infectivity. Future studies of SR-BI SNPs will provide insights into the host-virus interaction and will help identify new treatments for HCV infection.

Terminology
-----------

HCVpp, referred as HCV pseudoparticles, were prepared by inserting HCV envelope proteins into pLenti6 transfer vector, and transfected into HEK 293T cells together with helper plasmids Gag/Pol and Rev. HCVcc, referred as real HCV virus particles in cell culture, is prepared by transfection of whole genomic HCV RNA transcripts into Huh 7 or its derived cell lines.

Peer-review
-----------

The manuscript is well written. Authors demonstrated that single amino acid polymorphism of SR-BI S112F decreased the infectivity of HCVcc in SR-BI silenced Huh 7 cells. This is the first study evaluating the effect of SR-BI S112F on the infectivity of HCV even though in the *in vitro* cell culture system. The study showed that SNPs of SR-BI were critical for HCV infectivity.
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